June 26, 2017

3D Bioprinter Produces Skin for Tranplants

3D Bioprinter Prints Functional Human Skin Adequate for Transplant

3dprintedskin-frankmagliochetti-healthcareinnovationA team of researchers in Spain reports the development of a new three-dimensional (3D) printer capable of printing human skin suitable for transplant into patients. The printed skin is also suitable for testing drugs and cosmetics.

The team included several groups of researchers, including a group from the Universidad Carlos III de Madrid (UC3M) in Spain. The researchers describe their breakthrough in the scientific journal, Biofabrication.

3D Printing and Skin Production

3D printing has been around since the 1980s, when Charles (Chuck) Hull introduced the first stereolithography apparatus (SLA), but the 3D printing industry is now experience rapid growth with applications in many fields. In medicine, 3D printing holds great promise in someday giving clinicians the ability to produce personalized, complex human tissues and organs on demand. One woman has already received a 3D printed ear from one company, for example, while another frankmagliochettireport-3d-bioprintercompany provides 3D printed implants that the recipient’s body converts to bone.

Three-dimensional printing of human body parts is challenging in a number of ways. Replicating the complexity of anatomical structures is difficult. Ensuring the printed tissue survive transplantation in a living body is another problem.

The scientists in Spain have already engineered plasma-based, two-layered skin used successfully in the treatment of burns and other wounds in a large number of patients. The primary drawback to this method is that it takes 3 weeks to produce enough skin to cover an extensive burn or large wound. Another disadvantage is that the scientists must perform much of the process manually.

3D printing is similar to a desktop computer printer except that the nozzle on the 3D printer exudes biological components rather than ink. These biological components, or bio-inks, are essential to successful 3D printing of human organs and tissues.

To aid in the process, a computer controls the nozzles and flow of biological components so that the nozzles deposit the bio-inks on precise locations on the print bed.

Prints large area of skin in 35 minutes

The authors of the study describe how their 3D printing method generated a 100 x 100 centimeter area of skin in just under 35 minutes.

Like the scientists’ existing plasma-based manual method of producing skin, the 3D printing technology generates two layers of skin – the epidermis and the dermis. The printer starts by producing the epidermis, including the protective outermost layer of keratinized cells, known as the stratum corneum. Next, it prints the thicker, deeper dermis, complete with collagen-producing frank-magliochetti_bioprinter-skinfibroblasts.

The new 3D printing method is faster, but still complex. One of the authors of the report, Juan Francisco del Cañizo of the Hospital General Universitario Gregorio Marañón and Universidad Complutense de Madrid, notes:

“Knowing how to mix the biological components, in what conditions to work with them so that the cells don’t deteriorate, and how to correctly deposit the product is critical to the system.”

The research team tested the printed skin in test tubes and in immunodeficient mice. Transplantation of the printed skin into the mice helped the scientists test the long-term effects in a living animal. In both tests, the 3D printed skin was very similar to human skin and indistinguishable from the manually produced bi-layered skin from plasma.

There are two main potential uses for this 3D skin – to produce skin for research and laboratory testing of drugs and cosmetics, and to produce person-specific skin from the patient’s own cells to treat burns and other wounds. The research team is also investigating ways to use the technology to print other human tissues.

Source

http://iopscience.iop.org/article/10.1088/1758-5090/9/1/015006/meta

Frank Magliochetti is Managing Partner for Parcae Capital

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release new sites dedicated to the industry. Frank currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Color Compounds in Foods Lowering Risk of Lung Cancer?

Color Compound in Some Fruits and Vegetables Could Lower Lung Cancer Risk in Smokers

A pigment in oranges, sweet red peppers, and other fruits and vegetables may lower the risk of lung cancer in smokers, according to a new study.

Nicotine is the primary addictive component of tobacco and some e-cigarette liquids. Medical scientists believe nicotine contributes to cancer promotion and progression by activating nicotinic acetylcholine receptors. The study results suggest that the color compound, known as beta-frankimagliochetti-healthcare-reportcryptoxanthin (BCX), reduces the number of these receptors. This means eating fruits and vegetables high in BCX might reduce the risk of lung cancer resulting from smoking.

Doctors diagnose about 222,500 new cases of lung cancer in the United States each year, according to the American Cancer Society, and more than 155,000 Americans will die from the disease each year. The American Lung Association notes that male smokers are 23 times more likely to develop lung cancer than are men who do not smoke, and female smokers are at 13 times greater risk of developing lung cancer than are non-smoking women.

Causing approximately 7,330 deaths among nonsmokers each year, exposure to secondhand smoke is also a risk factor for lung cancer.

Nicotine and the Growth of Lung Tumors

Tobacco smoke contains more than 7,000 compounds and many of these substances, upon inhalation, act as carcinogens to damage the cells lining the lungs. While nicotine does not cause lung cancer directly, the addictive compound can promote lung tumor growth.

Study co-author Xiang-Dong Wang, of the Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University in Boston, MA, and colleagues provide more insight into how nicotine promotes lung cancer.

frankmagliochetti-helathcare-ReportWhen inhaled, nicotine binds to nicotinic acetylcholine receptor α7 (α7-nAChR), which is a nicotine receptor lying on the surface of the lungs. The binding action prompts a signaling cascade that results in the proliferation of cells and the formation of new blood vessels. Cell proliferation and blood vessel formation are processes involved in the growth of cancer.

Nicotine also increases the production of nicotinic receptors, actually creating more α7-nAChR on which to bind. Providing more nicotinic receptors strengthens the signaling cascade, further encouraging the growth of lung cancer cells. In other words, the more a person smokes or suffers secondhand exposure to smoke, the more receptors he or she develops, the stronger the process encouraging the growth cancer.

Wang and colleagues think that consuming BCX could effectively reduce the number of α7-nAChR receptors on the lungs, thereby decreasing the potential growth of lung cancer cells.

BCX reduced lung tumor growth in laboratory mice

BCX is a carotenoid that gives yellow, orange and red fruits and vegetables their color. Oranges, tangerines, butternut squash, and sweet red peppers contain beta-cryptoxanthin.

In an earlier study, Wang and a team of researchers observed an association between eating foods rich in BCX and a lower risk of lung cancer in humans. In this study, the team focused on pinpointing the mechanisms underlying the link between a BCX-rich diet and lowered risk of lung cancer in smokers.

The scientists administered a daily injection of a carcinogen derived from nicotine to two groups of mice. The test group of mice also received a daily dose of BCX before and after the nicotine injection. The researchers found that, compared with the mice that did not receive the carotenoid, the test group experienced a 52-63 percent reduction in lung tumor growth.frank magliochetti-healthcare-report

The researchers determined 870 micrograms, which is the equivalent to one sweet pepper or two tangerines per day for humans, as the most effective daily dose of BCX for reducing lung tumor growth.

The team then tests BCX on human lung cancer cells, both with and without α7-nAChR. They discovered that lung cancer cells with α7-nAChR receptors were less likely to spread after exposure to the color compound, as compared with lung cancer cells without those receptors.

Further research could provide a better understanding of how consuming foods rich in beta-cryptoxanthin might affect the development of lung cancer in humans.

Source

http://cancerpreventionresearch.aacrjournals.org/content/9/11/875

http://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html

http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet.html?referrer=http://www.medicalnewstoday.com/articles/315404.php

Frank Magliochetti is Managing Partner for Parcae Capital

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release new sites dedicated to the industry. Frank currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

New Study on Personal Health Care Spending

New Study Sheds Light on Personal Health Care Spending Trends in the U.S.

The amount of dollars the Unites Spends on healthcare surpasses every other nation on the planet; all in all accounting for 17% of the economy in the U.S.

Frank Magliochetti

People spend more for health care in the United States than in any other nation on earth and, according to results of a new study published in JAMA, they spend more on diabetes and ischemic heart disease than on any other health condition.

Health care spending continues to rise in the U.S., now accounting for 17 percent of the nation’s economy. health-spending-Frank-MAgliochetti-ReportDespite this spending, there is very little information on how spending varies by condition, age and through time. Joseph L. Dieleman, PhD, from the Institute for Health Metrics and Evaluation, University of Washington and a team of researchers hoped to estimate national spending on personal health care by various factors.

U.S. Spending on Health Care Trends

The researchers included 183 sources of data in the study. Data sources included insurance claims, government budgets, household surveys, facility surveys, and official U.S. records from 1996 to 2013. The scientists grouped ICD-9 codes to form 155 conditions, such as diabetes and ischemic heart disease, for consideration in the study.

One of the more interesting findings of the study was that many of the top 20 conditions of health care spending were chronic conditions with a relatively high prevalence and health burden – many of them were also preventable. This group of conditions included diabetes, ischemic heart disease, chronic obstructive pulmonary disease (COPD), and cerebrovascular disease, all of which are attributable to modifiable risk factors.

Total costs of care

Americans spent $30.1 trillion on personal health care during the years included in the study. The researchers looked at how Americans spent that money, estimating the costs of treating 155 conditions. They found that, at an estimated $101 billion, Americans spent the most on treating diabetes. Spending for ischemic heart disease came in second at $88 billion; spending for low back and neck pain was a close third at $87 billion.

Increases in costs of care

Spending for personal health care increased for 143 of the conditions investigated over the course of the study. Spending on low back and neck pain increased $57 billion during those 18 years, and spending on diabetes US-healthcare-costs-FrankMagliochettiincreased $64 billion during that period.

Of all the conditions included in the study, 57 percent of spending went towards the top 20 conditions. Spending on emergency care and retail pharmaceuticals rose the fastest, at 6.4 percent and 5.6 percent annual growth rate, respectively. When it came to spending on diabetes, 57.6 percent went to pharmaceuticals while 23.5 percent was for ambulatory care.

The study was important in that it was the first to provide modeled estimates of U.S. personal health care spending. The results were revealing in that they showed that diabetes, ischemic heart disease, and low back and neck pain presented the highest costs to American consumers. The study was limited in that it used population-weighted data to represent total national spending, which excludes incarcerated persons and those receiving care from a Veterans Affairs (VA) facility. The University of Washington institutional review board reviewed and approved the project.

The information presented in the study may be useful to health care policy makers and health care providers working towards making health care spending more cost effective for the conditions that most commonly affect people living in the United States.

Source

http://jamanetwork.com/journals/jama/fullarticle/2594716

Frank Magliochetti is Managing Partner for Parcae Capital

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release new sites dedicated to the industry. Frank currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

NSAIDs May Prevent Colorectal Cancer

NSAIDs May Prevent the Development of Colorectal Cancer after Polyp Removal

A recent study published in the British medical journal suggests that NSAIDs may help prevent colorectal cancer after polyp removal – This post goes into more detail on the study.

Frank Magliochetti

Taking non-steroidal anti-inflammatory drugs (NSAIDs) may prevent the recurrence of advanced neoplasia, a type of polyp that is the precursor of colorectal cancer, after the surgical removal of pre-existing polyps. Recurrence rates of benign polyps and advanced neoplasia are quite high, so clinicians are eager to find easy-to-follow treatments to reduce recurrence.frankmagliochettireport-healthcare-cancer-treatments

A team of scientists from across the United States recently collaborated with Mayo Clinic researchers to determine how well NSAIDs, aspirin and other supplements prevent the recurrence of precancerous or cancerous polyps. The results of the study, published in the British medical journal BMJ suggest NSAIDs may offer the greatest protection.

About Colorectal Cancer

Colorectal cancer is the third most common type of cancer in men and woman in the United States, according to the Centers for Disease Control and Prevention (CDC), and it is the second leading cause of cancer-related deaths among cancers affecting both men and women.

Colorectal cancer, characterized by abnormal cell growth in the colon or rectum, is one of the few preventable types of cancers. Removing precancerous polyps during colonoscopy prevents those polyps from turning cancerous but it does not prevent recurrence of advanced neoplasia, also known as advanced adenomas or adenomatous polyps. A study published in PLOS showed a recurrence rate of 50.5 percent for polyps, and a 32.9 percent recurrence rate for neoplasia.

Research Suggests Non-Aspirin NSAIDs Reduces Risk of Recurrence of Precancerous Polyps

The results of the BMJ study showed that non-aspirin NSAIDs, particularly ibuprofen, work better than aspirin or many other nutritional supplements for most patients when it came to preventing the growth of advanced neoplasia. The researchers note that, because most colorectal cancers develop from neoplasia, frank-magliochetti-report-healthcare-cancer-preventionchemoprevention with NSAIDs has a favorable risk to benefit profile when it comes to reducing recurrence in those with a history of high-risk neoplasia.

  1. Hassan Murad, M.D., preventive medicine physician and clinical epidemiologist at Mayo Clinic, is the study’s senior author. “Approximately 85 percent of all colorectal cancers are thought to result from untreated adenomatous polyps,” says Murad, M.D., in a press release published by Mayo Clinic. “If we can find a way to stop their growth, we could prevent a majority of these cases.”

“We knew that aspirin and other NSAIDs have a protective effect, and that a number of other nutritional supplements have also been studied for their effectiveness in preventing cancer,” says Dr. Murad. “What we didn’t know is how they compared to each other.”

The research team conducted a meta-analysis from data obtained from 15 randomized control trials. The scientists reviewed information from 12,234 patients who were taking various supplements and medications. The researchers looked at low- and high-dose aspirin therapy, NSAIDs, vitamin D, calcium, and folic acid, and then compared each treatment alone and in different combinations.

Analysis of the information showed that non-aspirin NSAIDs worked better than all the other therapies for preventing adenomatous polyps recurrence within three to five years after removal through colonoscopy. Because these non-aspirin NSAIDs pose other health risks, this treatment may not be appropriate for all patients.

“It is important that patients and doctors have a discussion on the various risks and benefits of any medication or other therapy,” says Murad. “While a research publication may contain promising findings, it is generalized information, and each individual is different. So their care will be individualized, as well.”

Source

http://www.bmj.com/content/355/bmj.i6188

https://www.cdc.gov/cancer/colorectal/statistics/

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0050990

Frank Magliochetti is Managing Partner for Parcae Capital

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release new sites dedicated to the industry. Frank currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Trends 2017: Human Metapneumovirus (hMPV)

Human Metapneumovirus Trends

Frank Magliochetti Report

Human  is a respiratory virus that can cause lower and upper respiratory tract infections, including bronchitis and pneumonia, and may even trigger asthma. Acute respiratory tract infections are the most common reason for doctor office visits, according to the American College of Physicians. Illness associated with hMPV can be severe; the virus is associated with an associated 20,000 hospitalizations of children aged 5 and younger in the United States each year. Elderly and immunocompromised individuals are at higher risk of the disease.

History of hMPV

Until just a few short years ago, the hMPV virus was different from other common respiratory viruses as PCR-based methods using virus genome-specific primers and immunological assays using virus-specific antibodies failed to identify the pathogen. It was only after the application of a molecular biology tool, known as randomly primed PCR, could researchers identify portions of the virus’s genomic sequence.frank-magliochetti-report_hmpv_metapneumovirus_

In 2001, a team of scientists headed by B.G. van den Hoogen identified hMPV in children with respiratory tract infection by using randomly primed PCR to obtain a genomic sequence of the pathogen. Based on the sequence data currently available, the human metapneumovirus seems to be a close relation of another member of the Metapneumovirus genus, the avian pneumovirus.

Since its discovery just over 16 years ago, laboratory testing has confirmed the virus in patients around the globe. Today, scientists recognize human metapneumovirus as an emerging pathogen that may have been causing respiratory tract infections for at least 60 years.

Testing and Treatment of hMPV

american_lung_association_frankmagliochettireportTesting is not yet widely available, according to the American Lung Association, but the most common method is by swabbing and testing secretions from the nose or throat. Bronchoscopy may be used to collect specimens in hospitalized patients.

There is no direct treatment for hMPV infection so treatment focuses on alleviating symptoms of fever, runny nose, cough and sore throat. The symptoms of human metapneumovirus typically last for 2 to 5 days. Management focuses on the use of over-the-counter fever and pain remedies along with decongestants.

hMPV Trends in the United States and By Region

hMPV infections typically develop during flu season in winter and early spring, according to a report published in April 2016, and typically after the onset of respiratory syncytial virus (RSV).

The Centers for Disease Control and Prevention (CDC) collects weekly laboratory PCR and antigen testing result data and cdc-frankmagliochettireporttracks trends of hMPV by region. In nationwide testing, positive results by PCR testing for the year 2016 peaked at 9 percent in the middle of February while the number of positive antigen tests peaked at 9.5 percent in March.

hMPV peaks later in the Northeast, with positive PCR test results peaking at the end of February and March and a spike in positive antigen results of 10.4 percent at the end of April 2016.

The Midwest had the highest rates of positive test results in 2015, with about 13 percent of hMPV tests returning positive results. The southern section of the United States sees its peak hMPV tests in March with a 10 percent positive antigen testing rate and 8 percent positive PCR rate. The West had high hMPV positive test rates throughout February, reaching their 2016 PCR positive test peak of 11.3 percent in the last week of February. Antigen detection tests yielded unsteady results in that region.

The CDC and other agencies will likely collect more information about hMPV trends and treatments as diagnostic tools become more available.

Source

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539100/

https://www.acponline.org/acp-newsroom/acp-and-cdc-issue-advice-for-prescribing-antibiotics-for-acute-respiratory-tract-infections-in

http://www.medscape.com/viewarticle/861392

https://www.ncbi.nlm.nih.gov/pubmed/11385510

http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/human-metapneumovirus-hmpv/diagnosing-hmpv.html?referrer=http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/human-metapneumovirus-hmpv/learn-about-hmpv.html?referrer=https://www

http://pediatrics.aappublications.org/content/early/2016/03/31/peds.2015-2927

https://www.cdc.gov/surveillance/nrevss/hmpv/index.html

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release new sites dedicated to the industry  – .  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

5 Trends in New Medical Economy

5 Trends in the New Medical Economy-

Frank Magliochetti Report

Five key trends will shape the new medical economy, according to a November 2016 briefing report by the cloud-based healthcare IT solutions provider CareCloud.frankmagliochettireport
The medical economy is shifting away from fee-for-service and towards value-based care. The industry faces a host of new economic realities as various forces shape the business of medicine. Five trends in particular will influence the new medical economy.

Five Trends Shaping the Business of Medicine

1. Patients as payers
Patients will continue to seize control over their own healthcare costs as a response to skyrocketing out-of-pocket expenses and deductibles. Insurance deductibles have increased by 255 percent since 2006, according to a survey by InstaMed, and the average health insurance premium for family coverage has gone up by 83 percent since 2005. Because they pay out of their own pockets, consumers want the best treatment bang for their buck, including information about services, options, and treatment costs.
Patients are also becoming increasingly proactive in managing their own healthcare by gathering information on diagnosis, billing and treatments digitally. Nearly two out of three consumers participating in the InstaMed survey expressed interest in using Apple Pay or other mobile payment systems for healthcare bills. More than three out of four consumers prefer to pay their household bills through online payment channels. The internet frankmagliochettireport_medicaleconomytrendswill continue to be a rich source of information, health apps, data, and medical devices for patients. CareCloud predicts a surge in retail urgent care clinics and concierge practices that cater to consumer-minded patients.
2. Doctors as digital innovators
An increasing number of healthcare providers are adopting EHR systems, and are shifting from server-based systems toward cloud technology to take advantage of improved usability, faster upgrade cycles and more innovation. Providers will likely use more specialized technologies across multiple EHR platforms. Application programming interfaces (APIs) will help medical groups enhance services without having to replace entire base systems.
3. Fiscal stewardship
Hospitals and health systems will try to reduce costs as they shift towards value-based care and away from fee-for-service care. Financial stewardship promotes health in the general population by increasing overall access to care.
4. Entrepreneurs in medicine
Exciting opportunities are ahead for “doctorpreneurs” and other medical professionals who either build new medical groups or acquire existing ones. Medical entrepreneurship offers the twin benefits of earning profits and social good.
While private equity investors traditionally invest in medical groups promising high reimbursement potential, such as dermatology and pain management, today’s medical entrepreneurs are looking at primary care groups.
5. Information retains its crown as king
The push to digitize medical records coupled with the rapid shift to value-based care has created a mountain of information. The information benefits population health management by making healthcare proactive rather medicaleconomytrends-frankmagliochettithan reactive, identifying at-risk patients and promoting early intervention. The plethora of data and new technologies now allows each patient to create a custom care plan tailored to their medical history. The development of intelligent apps that leverage data and analytics tools will help manage and disseminate this information.
Changing regulations, patient engagements and new economic realities are driving healthcare towards a value-based, consumer-centric model. Healthcare technology will evolve to focus more on adaptability and innovation.

Source
http://on.carecloud.com/thenewmedicaleconomy.html
http://www.instamed.com/blog/trends-impacting-the-healthcare-payments-mar

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release new sites dedicated to the industry  – .  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Smoking Statistics: Focus on the Northeast

Smoking Statistics: Northeast USA

Cigarette smoking is still the leading cause of preventable death in the United States, according to the Centers for Disease Control and Prevention (CDC), claiming more than 480,000 lives each year. Despite decades of anti-smoking campaigns, which have been largely successful at reducing the number of cigarette smoking and death rates associated with the habit, smokingstatistics-frankmagliochettireportabout 36.5 million Americans still smoke. About 1 in 5 deaths in the U.S. are associated with smoking. Smoking remains high in certain segments of the population and in certain areas of the country. Many states are trying to reduce their number of smokers by raising tax on cigarettes, and investing in tobacco cessation programs and tobacco prevention programs.
Young adults, males, people with low education levels and those living below poverty level, lesbians, gays and bisexuals, the disabled and individuals of certain races or ethnicities are more likely to smoke. About 13 percent of people aged 18 to 24 smokes and 17.7 percent of people aged 25 to 44 smoke.
Smoking Rates by Geography
The percentage of smokers has declined in the U.S. from 20.9 percent in 2005 to 15.1 percent in 2015. Current cigarette smoking was highest in the Midwest at 18.7 percent and lowest in the West at 12.4 percent. About 13.5 percent of people living in the Northeast smoke cigarettes.
A fact sheet released November 2017 by Campaign for Tobacco-Free Kids presents state-specific tobacco-related data in very different ways. It ranks states according to adult smoking rates, adult smoking ranks, pregnant smoking ranks and annual smoking deaths. The report also looks at youth smoking rates, the number of kidsfrankmagliochettireport_smokingstatistics alive who will become smokers, and the number of children alive who will eventually die from smoking in each state. Finally, the chart lists the health costs associated with smoking, per pack tax rates and ranks, state financing for tobacco cessation programs, and tobacco prevention spending.
Kentucky has the highest adult smoking rate in the country at 25.9 percent, and the state has a relatively high percentage of pregnant smokers and youth smokers. This high smoking rate may be the result of the state’s relatively low per-pack price of $4.86. Utah has the lowest adult smoking rate at 9.1; retail price for a pack of cigarettes here is $6.43.
There is relatively low tobacco use in the Northeast; much of the low tobacco use there has to do with the relatively high per-pack price and hefty tax rates on cigarettes. At 13.5 percent, Connecticut and New Jersey are tied as the third lowest adult smoking rates in the country. Connecticut has the second highest cigarette tax rate in the nation – $3.90 per pack. New Jersey also has a high cigarette tax at $2.70 per pack.
The average price for cigarettes in Massachusetts is $9.08 per pack and the state charges $3.90 per pack in tax, the fourth highest tax in the nation. The high price of cigarettes pays off, though, as the state has the sixth lowest rate of adults smoking and one of the lowest youth smoking rates in the country.
Northeastern states and other states in the nation may continue to reduce smoking rates – and death rates associated with smoking – by increasing taxes on cigarette products and investing in tobacco cessation and prevention programs.

Source:
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Medical 3D Printing Advancements

Advancements in Medical 3D Printing

Three-dimensional (3D) printing has been around since the 1980s, when Chuck Hull patented the mechanical process of printing successive layers of material to create objects. Known as stereolithography or additive manufacturing, the process quickly spread beyond industry into a number of sectors, including medicine.
3d-printing-and-health_frankmagliochettireportA 3D printer is similar to a standard computer printer except that, instead of ink, liquid plastic, metal, polyvinyl alcohol, and other materials flow through its print nozzles. 3D printers are unique in that the process can create three-dimensional solid-state objects made from a variety of materials. Printed objects can be as simple or as intricate as needed by the designer without requiring extra steps in the manufacturing process.
In 1999, surgeons grew a human bladder by layering human bladder cells onto 3D printed scaffold then later transplanted the bladder into the patient that donated the cells. In 2002, scientists used bio-ink replicating kidney tissue to print a functioning kidney.
There have been several major advancements since the earliest days of medical 3D printing. While it is still not possible to print out an entire organ suitable for transplant, it is possible to use three-dimensional printing to create scaffold for growing organs, grow tissues for laboratory testing, make skin grafts for burn victims, print sheets of cardiac tissue that beats like a heart, and more.
State of the Art Medical 3D Printing
Scientists from Harvard University recently made the first 3D printed organ-on-a-chip with integrated sensing, which allows researchers to collect reliable data during laboratory studies. These organs-on-chips, also known as medical-3d-printing_frankmagliochettireportmicrophysiological systems, closely match the properties of a specific disease or individual patient cells suitable for use in the laboratory. These chips simplify data acquisition and allow researchers to change and customize the study design system, opening new avenues for in vitro tissue engineering, toxicology and drug screening research.
Other researchers use direct laser writing to shape and form 3D printed undifferentiated stem cells to create complex 3D structures for various biomedical applications. Another company recently released a realistic-feeling 3D printed arm modelstudents can use to learn how to suture skin. The company, San Draw, had previously released a 3D printed arm model suitable for practicing injections. The 3D printed skin simulates the anatomy and feel of real human skin to improve student training.
3D printing presents nearly unlimited potential in the production of surgical instruments, including forceps, hemostats, scalpel handles, clamps, and even surgical smoke evacuators. 3D printed surgical tools come out of the 3d-printing_medical-frankmagliochettireportprinter completely sterile and ready to use, saving both time and money in sterilization, packaging and storage. Printed tools also cost one-tenth as much as stainless steel tools. 3D printing could therefore boost surgery access in low-income areas and reduce the risk of infection in areas with limited access to sterilizers.
Researchers can print out and expose various body tissues to chemicals and other substances to study the reaction of toxins on healthy tissue. Now scientists can print out cancer cells and other types of disease cells to study how tumors grow and develop, and to evaluate the effects of various treatments on those printed cells.
Research and development of medical 3D printing will likely accelerate as scientists find new uses for the additive manufacturing process and manufacturers learn new techniques for making medical and surgical products. 3D printers will certainly become more commonplace in the surgical suite and in laboratories in the coming years.

Source
https://3dprintingindustry.com/3d-printing-basics-free-beginners-guide/history/
http://www.nature.com/nmat/journal/vaop/ncurrent/full/nmat4782.html
https://www.researchgate.net/publication/309393081_3D_microfabrication_of_complex_structures_for_biomedical_applications_via_combination_of_subtractiveadditive_direct_laser_writing_and_3D_printing
https://3dprint.com/152558/san-draw-medical-suture-training/
https://3dprint.com/6652/3d-print-medical-tools/

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Augmented Reality: A Disruptive Trend that is Changing Healthcare

Augmented Reality: A Disruptive Trend that is Changing Healthcare

Google Glass and other types of augmented reality (AR) never really took hold in the consumer market but the advanced technology is now poised to be a disruptive trend that will forever change healthcare for patients and providers.frankmagliochettireport_medicalaugmentedreality
A Q4 2016 report by ABI Research suggests augmented reality will gain momentum as medical professionals seek out new tools and technologies to improve care and outcome for their patients. The research firm suggests regulatory activity will push the medical profession towards AR.

About Augmented Reality in Medicine

Augmented reality is a live view of a real-world environment supplemented with computer-generated sounds, graphics or other sensory input. Unlike virtual reality, which entirely replaces the real world with a simulated one, augmented reality replaces only certain elements.
AR can include “see what I see” applications, education and training. “See what I see” apps can transmit what EMTs see to emergency department physicians. In medical applications, augmented reality applications can simulate how it would feel to have certain medical conditions.
frankmagliochetti_augmentedrealityinmedicineAR applications (apps) can help patients check visual symptoms against a medical database or share information in real time with their doctors. Patients with hearing problems can use AR apps and their smart phones to convert auditory information, such as the screech of brakes or a loudspeaker announcement on an airplane, into text displayed on the smart phone. AR apps can highlight maps of wheelchair-friendly routes when an individual visits a city for the first time.
Augmented reality can provide medical training to a large number of students, even those living in remote or impoverished areas. Students use AR to practice surgical techniques, or even allow experienced surgeons to practice procedures on a three-dimensional AR rending of a patient before performing the procedure on the actual patient.

Augmented Reality Applications are Already in Use

Eye Decide by OrcaMD is an educational application that could potential improve patient compliance. This education tool simplifies complex eye conditions and treatments in a way that improves knowledge, understanding and retention. Users can view the eyeball from any angle, with and without skin. Eye Decide also demonstrates the effects of cataracts, age-related macular degeneration (AMD), and other eye conditions, so that patients can see what a particular disease will eventually do to their vision without proper treatment.
AccuVein displays a map of a patient’s vein to make placing needles easier and more accurate. The healthcare practitioner uses a handheld scanner that detects heat radiating from the veins, converts information gathered about that heat into a map of the veins, and then projects this map onto the patient’s skin. AccuVein enjoys a 40 percent annual growth rate. By the middle of 2015, this augmented reality app had already helped more frankmagliochetti_report-augment-reality-healthcarethan 10 million patients. Sales will likely continue at a robust pace as patients and nurses demand the technology to reduce the average number of “sticks” involved in placing an intravenous (IV) needle.
Many legally blind people still have some vision but cannot see well enough to recognize faces, drive, read, or avoid obstacles in their path. VA-ST is a visor that combines a 3D camera with a computer to enhance vision by improving contrast, and highlighting edges and features. Users can even pause or zoom video for a clearer view. This technology will become more popular as the population of the United States ages and suffers age-related vision loss.
Like other industries, medicine leverages new technology to improve efficiencies and performance. The move from a per-service reimbursement structure towards one that focuses on quality of care will spur growth of augmented reality in medical settings.

Source
https://www.abiresearch.com/market-research/product/1025909-ar-in-telemedicine-training-and-first-resp/
https://itunes.apple.com/us/app/eye-decide-education-engagement/id454280553?mt=8
https://orcahealth.com/
http://www.accuvein.com/inf/
http://www.accuvein.com/2015/06/vein-visualization-emerges-as-premier-augmented-reality-application/
http://www.va-st.com/smart-specs/

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital

Tdap Lead to Increased Trend in HPV Vaccines

Requiring Tdap May Increase HPV Vaccination in Adolescent Girls

About 9 in 10 people will get a human papillomavirus (HPV) infection at some point in their lives, according to the Centers for Disease Control and Prevention (CDC). HPV infections are associated with health problems, including several types of cancer in men and women, which means HPV infection is an urgent health problem. A new study shows that teenage girls were more likely to start the HPV vaccine series in states where schools required the meningococcal vaccine and/or the tetanus, diphtheria, and pertussis (Tdap) booster prior to admission.
frankmagliochetti_tdap-vaccineNationwide, 63 percent of girls have received at least one dose of the vaccine, and half of all boys have started the series. Low HPV vaccination coverage is an urgent public health problem and improving HPV vaccination rates will save lives. The nation’s high Tdap vaccination rate of 86 percent shows that high HPV vaccination coverage is possible.
Most cervical cancers, anal carcinomas, and oropharyngeal cancers are the result of infection with high-risk HPV strains. While vaccines capable of preventing HPV related cancers are available, low usage limits their utility.
Previous attempts at improving HPV vaccination included state laws requiring the vaccine, but many of these laws allowed for exemptions for any reason. Because parents could opt out for nearly any reason, these state laws have been largely ineffective at increasing HPV vaccination coverage.
Improving HPV Vaccination Coverage by Vaccinating Against Other Diseases
To identify policies that could improve suboptimal HPV vaccination rates, the authors of the study sought to evaluate the relationship between adolescent vaccination and states’ school entry requirements. In the study, published in the medical journal Pediatrics, researchers compared HPV vaccination coverage in teenage girls aged 13 to 17 years across states with different vaccination requirements for school entry.
The authors gathered information from published data regarding school entry requirements from the Immunization Action Coalition (2007-2012) and vaccination rates from the National Immunization Survey-Teen (NIS-Teen, 2008-2012). They analyzed Tdap booster and meningococcal vaccination rates and evaluated the possibility of increasing HPV vaccination rates by “spillover effect,” meaning schools that require vaccinations as a condition of attendance could have higher rates of HPV vaccination.

The Results

The researchers found that requiring vaccination for admission to school did indeed improve vaccination rates for HPV. Vaccination requirements also boostedfrankmagliochettireport__hpv_vaccine coverage for Tdap and meningococcal vaccinations.
Compared with other states, those states with Tdap booster and meningococcal vaccination had a 22 and 24 percentage point increases in coverage for these vaccines, respectively. States with HPV vaccination requirements had less than 1 percentage point increase in coverage. Requiring Tdap booster and meningococcal vaccinations caused an 8 and 4 percentage point spillover increases for HPV vaccination coverage.
The study was limited in that it failed to account for confounding variables, such as religion, ethnicity, and parental education. Furthermore, the study did not account for the types of school attended, as homeschooled adolescents and teens attending private schools may not be subject to the same vaccination requirements. Despite these limitations and considering the controversy surrounding HPV legislation, utilizing the spillover effect from meningococcal and Tdap vaccination may be an effective approach to improving HPV vaccination coverage.

SOURCE:

http://www.cdc.gov/vaccinesafety/vaccines/hpv-vaccine.html

http://pediatrics.aappublications.org/content/early/2016/11/05/peds.2016-1414?sso=1&sso_redirect_count=1&nfstatus=401&nftoken=00000000-0000-0000-0000-000000000000&nfstatusdescription=ERROR%3a+No+local+token

http://www.cdc.gov/hpv/infographics/vacc-coverage.html

Frank Magliochetti is Managing Partner for Parcae Capital.

  • North Andover, Massachusetts

This column of posts is directed at the Healthcare Industry.  Frank plans to release a new site dedicated to the industry.  He currently assists companies who are building, restructuring, transforming and resurrecting there business’s. An example of his client base are, Xenetic Biosciences , IPC Medical Corp, Just Fellowship Corp, Environmental Services Inc., Parsons Post House LLC, ClickStream Corporation as well as having a business talk radio show; The Business Architect on the URBN network.

frankmagliochetti_ParcaeCapital